Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Clin Mol Hepatol. 2018 Dec;24(4):424-429. doi: 10.3350/cmh.2017.0032. Epub 2017 Nov 14.
Hepatocellular carcinoma (HCC) is the sixth most common cause of death worldwide and the main cause of primary liver cancer. The principle problem of HCC is the poor prognosis, since advanced HCC reportedly has a median survival of only 9 months. The standard therapies are sorafenib and regorafenib, but the outcomes remain unclear. We report a 60-year-old man with advanced HCC with right adrenal gland metastasis and portal vein tumor thrombosis, who showed a complete response to multiple applications of an interdisciplinary therapy.
肝细胞癌(HCC)是全球第六大常见的死亡原因,也是原发性肝癌的主要原因。HCC 的主要问题是预后不良,因为据报道晚期 HCC 的中位生存期仅为 9 个月。标准疗法是索拉非尼和regorafenib,但疗效仍不明确。我们报告了一例 60 岁男性,患有晚期 HCC,伴有右肾上腺转移和门静脉癌栓,经多次多学科治疗后达到完全缓解。